WHWK
Whitehawk Therapeutics, Inc.2.4000
+0.0400+1.69%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
113.11MP/E (TTM)
-Basic EPS (TTM)
-0.64Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
Q2 loss widens on ADC push
Whitehawk Therapeutics reported a $52.6 million net loss for Q2 2025, up from $14.6 million last year, driven by a $38.0 million upfront payment under its WuXi ADC agreement and ramped R&D spending of $48.8 million. Cash swelled to $177.2 million, funding operations into 2028 while advancing three ADC programs toward IND filings by year-end for HWK-007 and HWK-016, and mid-2026 for HWK-206. Pipeline progress accelerates. Yet preclinical uncertainties loom large.
10-Q
Q2 FY2025 results
Whitehawk Therapeutics posted a Q2 net loss of $52.6M, up from $14.6M a year earlier, as revenue from the divested FYARRO business fell to zero from $6.2M y/y while R&D expenses surged 273% y/y to $48.8M, driven by a $38M upfront payment for the ADC Therapies license. The six-month period swung to net income of $20.4M from a $32.9M loss, thanks to an $87.4M gain on the March 2025 FYARRO sale for $102.4M cash, though operating loss widened to $70.0M from $35.1M y/y. Cash and short-term investments stood at $177.2M at quarter-end, bolstered by $94.5M net from a March PIPE financing, funding operations into 2028. The FYARRO Divestiture closed in March 2025 for $102.4M (all cash), eliminating commercial revenue but sharpening focus on preclinical ADCs targeting MUC16, PTK7, and SEZ6. Competition in the crowded ADC space remains fierce.
8-K
Annual meeting elects directors
Whitehawk Therapeutics held its annual stockholder meeting on June 11, 2025, with 61% of shares present. Stockholders elected Anupam Dalal, M.D., Mohammad Hirmand, M.D., and David Lennon, Ph.D. as Class II directors for terms ending in 2028, while shrinking the board from ten to nine seats. Advisory approval passed for executive compensation, but with notable opposition; BDO USA, P.C. ratification sailed through unanimously. Board refresh signals tighter governance amid biotech pressures.
AAGH
America Great Health
0.00+0.00
AKTX
Akari Therapeutics Plc
0.25-0.16
CBIO
Crescent Biopharma, Inc.
12.92-0.29
HCWB
HCW Biologics Inc.
1.78-0.09
IMA
ImageneBio, Inc.
6.25+0.08
JBIO
Jade Biosciences, Inc.
16.04+0.79
LADX
LadRx Corporation
0.11+0.00
MRSN
Mersana Therapeutics, Inc.
29.05+0.46
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
RENB
Lunai Bioworks Inc.
1.42+0.00